GWAV Q3 2023 Earnings Loss per Share Reported at 175 as Company Focuses on Operational Improvements INVH Q1 2026 Earnings Strong EPS Beat Fails to Boost Sentiment as Stock Edges Lower Pulmatrix Q2 2025 Earnings Loss Per Share Widens Amidst No Revenue Disclosure BXP Q1 2026 Earnings Stellar EPS Beat Highlights Operational Strength GALT Q1 2026 Earnings WiderThanExpected Loss as ClinicalStage Biotech Continues RD Spend ABVX Q4 2025 Earnings Significant EPS Miss as DevelopmentStage Biotech Reports WiderThanExpected Loss